Sapient CSF Proteomics

Sapient’s offers mass spectrometry-based cerebrospinal fluid (CSF) proteomics services for an in-depth and unbiased approach to probe the proteomic landscape of CNS biology and neurodegenerative disease (ND), uncovering new biomarkers of early disease pathology and drug response.

Our discovery approach leverages Sapient’s single nanoparticle extraction system optimized for use in CSF, allowing for the capture and enrichment of low-abundance proteins, including neurofilament and tau proteins, as well as measure of thousands of additional biomarkers central to CNS diseases – including post-translational modifications (PTMs) on proteins. The nanoparticle system employs a specialized ‘capture-and-hold’ chemistry to limit the typical sample-to-sample and prep-to-prep variance that is associated with nanoparticle extraction, allowing for comprehensive and reproducible capture of proteins, including PTMs and proteoforms, in CSF.

In fact, our discovery workflows measure 3,600+ protein groups, comprising ~33,800 peptides, in less than 50 µl of CSF. This includes free proteins as well as exosomal and membrane-bound proteins released by the nervous tissue into CSF. Our nontargeted approach enables robust measure of established biomarkers and targets for ND, while also delivering significant discovery potential through the identification of differentially expressed proteins in CSF that are not yet well-established CNS biomarkers but that may represent robust novel targets.